Concepedia

Consensus on the management of advanced medullary thyroid carcinoma on behalf of the Working Group of Thyroid Cancer of the Spanish Society of Endocrinology (SEEN) and the Spanish Task Force Group for Orphan and Infrequent Tumors (GETHI)

Juan C. Galofré, Javier Santamaría Sandi, Jaume Capdevila, Elena Navarro González, Carles Zafón Llopis, Teresa Ramón y Cajal Asensio, José Manuel Gómez Sáez, Paula Jiménez‐Fonseca, Garcilaso Riesco‐Eizaguirre, Enrique Grande

Endocrinología y Nutrición · 2015 · 11 citations · 22 references

DOIFull text

Open access

Concepts

References

22

Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

Samuel A. Wells, Bruce G. Robinson, Robert F. Gagel et al. · Journal of Clinical Oncology · 2011 · 1.6K citations · Full text

, , +6

Cabozantinib in Progressive Medullary Thyroid Cancer

Rossella Elisei, Martin Schlumberger, Stefan Müller et al. · Journal of Clinical Oncology · 2013 · 1.2K citations · Full text

, , +14

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

Stephen R. Wedge, Donald Ogilvie, Michael Dukes et al. · PubMed · 2002 · 802 citations

, , +15

Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients

E Modigliani, R. Cohen, José‐Marie Campos et al. · Clinical Endocrinology · 1998 · 571 citations

, , +17

ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.

Francesca Carlomagno, Donata Vitagliano, Teresa Guida et al. · PubMed · 2002 · 570 citations

, , +17